Trending...
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- Spokane: Chat & Chew District 3 Council Members
- Spokane: 2026 Pools & Aquatics Information
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale
- Spokane: City Closures Planned for Juneteenth
- SafeBets Named Presenting Sponsor of IMCX 2026, Bringing Its No-Deposit Prediction Platform to the Creator Economy's Deal-Making Conference
- A New Pulse for Cardiac Care in Baltimore: St. Elizabeth Rehab & Nursing Welcomes Dr. Hakim Uqdah and Expands Advanced Heart Program
- Inframark–Slater Joint Venture Selected to Manage Fulton County Wastewater Operations
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Spokane: Housing and Human Services Dept. Provides Update on Housing and Homelessness Initiatives
- Boston Industrial Solutions' Natron® 717N Series UV LED Ink Receives CPSIA Certification
- Spokane City Clerk To Retire After 30 Years In Role, Successor Named
- purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
- Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
- UK Financial Ltd Publishes Maya Preferred Public Proof Package and CoinMarketCap Supply Verification Evidence
- Haven Treatment Center Launches Community Haircut Drive to Help Local Families
- Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
- Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
- CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets
- Custom Disposables - Wholesale Packaging Solutions for restaurants, food chains, and food distributors
- California Security Glass is an affordable bulletproof glass installation company in LA serving a variety of neighboring cities
- Allstream Energy Partners Announce Media Partnership with the 2026 EPC Show - The Energy Projects Conference
- STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
- West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
- Spokane: Chat & Chew District 3 Council Members
- CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
- Keynote Speaker announced for the 2026 NCIHC Language Access Congress
- Tacoma: Statement from Council Member Latasha Palmer Regarding Stable, Safe, and Affordable Housing
- Brilliant Minds to Gather in Fort Worth for National Mensa Event